BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Eva M. Teegen, Michael Dürr, Max M. Maurer, Franziska Eurich, Antonia Vollbort, Brigitta Globke, Marcus Bahra, Hendrik Blaeker, Johann Pratschke, Dennis Eurich. Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrenceTransplant Infectious Disease 2019; 21(1): e13020 doi: 10.1111/tid.13020
2
Maria A. Sorbera, Michelle L. Friedman, Rebecca Cope. New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal ImpairmentJournal of Pharmacy Practice 2017; 30(3): 359 doi: 10.1177/0897190016632128
3
Jeonghwan Lee, Jang-Hee Cho, Jong Soo Lee, Dong-Won Ahn, Chan-Duck Kim, Curie Ahn, In Mok Jung, Duck Jong Han, Chun Soo Lim, Yon Su Kim, Young Hoon Kim, Jung Pyo Lee. Pretransplant Hepatitis B Viral Infection Increases Risk of Death After Kidney TransplantationMedicine 2016; 95(21): e3671 doi: 10.1097/MD.0000000000003671
4
Anna Maruyama, Nilufar Partovi, Eric M. Yoshida, Siegfried R. Erb, Vladimir Marquez Azalgara, Trana Hussaini. A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney diseaseNephrology Dialysis Transplantation 2015; : gfv361 doi: 10.1093/ndt/gfv361
5
Christophe Hézode, Piero L. Almasio, Stefan Bourgeois, Peter Buggisch, Ashley Brown, Moises Diago, Yves Horsmans, Lawrence Serfaty, Ferenc Szalay, Giovanni B. Gaeta, Ramon Planas, Michael Schlag, Isabelle Lonjon-Domanec, Edmund Omoruyi, Ralph DeMasi, Stefan Zeuzem. Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver diseaseLiver International 2017; 37(9): 1304 doi: 10.1111/liv.13376
6
Parmvir Parmar, Curtis Cooper. Management of hepatitis C in a patient undergoing solid organ (kidney) transplantOfficial Journal of the Association of Medical Microbiology and Infectious Disease Canada 2018; 3(4): 231 doi: 10.3138/jammi.2017-0009
7
Jose D. Debes, Paola Ricci. Acute liver failure during hepatitis C treatment with sofosbuvir and ledipasvirDigestive and Liver Disease 2015; 47(12): 1091 doi: 10.1016/j.dld.2015.08.016
8
Fayda Ibrahim Abdel Motaleb, Enas Samir Nabih, Sherif Moneir Mohamed, Nehal Samir Abd Elhalim. Up-regulation of circulating miRNA146a correlates with viral load via IRAK1 and TRAF6 in hepatitis C virus-infected patientsVirus Research 2017; 238: 24 doi: 10.1016/j.virusres.2017.05.026
9
Adriana Dejman, Marco A. Ladino, David Roth. Treatment and management options for the hepatitis C virus infected kidney transplant candidateHemodialysis International 2018; 22: S36 doi: 10.1111/hdi.12646
10
Noha Mohamed Hany, Abd‐El‐Rahman M. A. Hammouda, Enas Samir Nabih, Sherif Moneir Mohamed. The potential regulatory role of miR16 to the interplay between interferon and transforming growth factor beta pathways through IRF3 and SMAD7 in hepatitis C virus infected patientsJournal of Cellular Biochemistry 2019; 120(8): 12694 doi: 10.1002/jcb.28537
11
C. Martin-Gandul, N. J. Mueller, M. Pascual, O. Manuel. The Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ TransplantationAmerican Journal of Transplantation 2015; 15(12): 3024 doi: 10.1111/ajt.13486
12
Paul J. Pockros, K. Rajender Reddy, Parvez S. Mantry, Eric Cohen, Michael Bennett, Mark S. Sulkowski, David E. Bernstein, Daniel E. Cohen, Nancy S. Shulman, Deli Wang, Amit Khatri, Manal Abunimeh, Thomas Podsadecki, Eric Lawitz. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal DiseaseGastroenterology 2016; 150(7): 1590 doi: 10.1053/j.gastro.2016.02.078
13
Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A. Kozarek, Asma Siddique. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal functionClinical and Molecular Hepatology 2017; 23(4): 316 doi: 10.3350/cmh.2016.0087
14
Chalermrat Bunchorntavakul, Tawesak Tanwandee. Treatment of Chronic Hepatitis C in Special PopulationsGastroenterology Clinics of North America 2015; 44(4): 883 doi: 10.1016/j.gtc.2015.06.002
15
C. Bunchorntavakul, K. Rajender Reddy. Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapyJournal of Viral Hepatitis 2016; 23(6): 408 doi: 10.1111/jvh.12534
16
Alessio Strazzulla, Giuseppe Coppolino, Concetta Di Fatta, Francesca Giancotti, Giuseppina D’Onofrio, Maria Concetta Postorino, Maria Mazzitelli, Selma Valerie Mammone, Innocenza Gentile, Laura Rivoli, Eleonora Palella, Tiziana Gravina, Chiara Costa, Vincenzo Pisani, Vincenzo De Maria, Giorgio Settimo Barreca, Nadia Marascio, Alfredo Focà, Giorgio Fuiano, Elio Gulletta, Carlo Torti. Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?World Journal of Hepatology 2016; 8(19): 815-824 doi: 10.4254/wjh.v8.i19.815
17
Marcella Visentini, Carmine Tinelli, Stefania Colantuono, Monica Monti, Serena Ludovisi, Laura Gragnani, Milica Mitrevski, Jessica Ranieri, Elisa Fognani, Alessia Piluso, Massimo Granata, Annalisa De Silvestri, Valeria Scotti, Mario U. Mondelli, Anna Linda Zignego, Massimo Fiorilli, Milvia Casato. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic reviewAutoimmunity Reviews 2015; 14(10): 889 doi: 10.1016/j.autrev.2015.05.013
18
Anna Maruyama, Trana Hussaini, Nilufar Partovi, Siegfried R. Erb, Vladimir Marquez Azalgara, Nadia Zalunardo, Neora Pick, Mark Hull, Eric M. Yoshida. Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney DiseaseCanadian Journal of Infectious Diseases and Medical Microbiology 2016; 2016: 1 doi: 10.1155/2016/8372835
19
Corinne Isnard Bagnis, Patrice Cacoub. Hepatitis C Therapy in Renal Patients: Who, How, When?Infectious Diseases and Therapy 2016; 5(3): 313 doi: 10.1007/s40121-016-0116-z
20
Akshanth R. Polepally, Prajakta S. Badri, Doerthe Eckert, Sven Mensing, Rajeev M. Menon. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV InfectionEuropean Journal of Drug Metabolism and Pharmacokinetics 2017; 42(2): 333 doi: 10.1007/s13318-016-0341-6
21
Vijaya L. Rao, Christopher Daugherty. Is it ethical to enroll a patient in a hepatitis C virus clinical trial when current standard of care is highly effective and safe?Clinical Liver Disease 2015; 6(5): 120 doi: 10.1002/cld.512
22
Marco Ladino, Fernando Pedraza, David Roth. Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney diseaseWorld Journal of Hepatology 2017; 9(19): 833-839 doi: 10.4254/wjh.v9.i19.833
23
Marco Ladino, Fernando Pedraza, David Roth. Hepatitis C Virus Infection in Chronic Kidney DiseaseJournal of the American Society of Nephrology 2016; 27(8): 2238 doi: 10.1681/ASN.2016010030
24
Rocío González-Grande, Miguel Jiménez-Pérez, Carolina González Arjona, José Mostazo Torres. New approaches in the treatment of hepatitis CWorld Journal of Gastroenterology 2016; 22(4): 1421-1432 doi: 10.3748/wjg.v22.i4.1421
25
Carmen Landaverde, Jennifer Wells, Rebekah Hamner, Janie L. Goldstein. Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infectionExpert Review of Gastroenterology & Hepatology 2016; 10(4): 419 doi: 10.1586/17474124.2016.1147346